|1.||Nishiya, Takayoshi: 3 articles (12/2008 - 06/2006)|
|2.||Kataoka, Hiroko: 3 articles (12/2008 - 06/2006)|
|3.||Mori, Kazuhiko: 3 articles (12/2008 - 06/2006)|
|4.||Manabe, Sunao: 2 articles (12/2008 - 10/2008)|
|5.||Hattori, Chiharu: 2 articles (12/2008 - 10/2008)|
|6.||Jindo, Toshimasa: 2 articles (12/2008 - 10/2008)|
|7.||Varikoti, Rohith A: 1 article (12/2015)|
|8.||Bharatam, Prasad V: 1 article (12/2015)|
|9.||Taxak, Nikhil: 1 article (12/2015)|
|10.||Jaladanki, Chaitanya K: 1 article (12/2015)|
|1.||Hypertension (High Blood Pressure)
08/01/1980 - "Eleven of these patients also had hypertension which was improved by tienilic acid. "
01/01/1979 - "In ten patients suffering from slight or moderate essential arterial hypertension, undergoing treatment with tienilic acid at 500 mg per day, various hemodynamic parameters were assessed by means of ecocardiographic and policardiographic studies carried out before, during and at the end of treatment. "
10/01/1981 - "[Tienilic acid and renal function in arterial hypertension]."
01/01/1981 - "Hemodynamic and metabolic long-term effects of tienilic acid in essential hypertension."
09/01/1980 - "Tienilic acid in the treatment of mild to moderate hypertension."
01/01/1979 - "Tienilic acid, a uricosuric diuretic, in the treatment of heart failure."
12/28/1979 - "Ticrynafen is useful in the treatment of hypertension and in selected cases of chronic congestive heart failure. "
01/01/1979 - "14 patients with congestive heart failure requiring diuretic therapy were randomly assigned to treatment with ticrynafen (TCRN) 250 mg or hydrochlorothiazide (HCTZ) 50 mg once or twice daily. "
01/01/1978 - "The effects of ticrynafen (250-500 mg) on salt-water and uric acid metabolism have been studied in 18 patients with no haemodinamic abnormalities or salt-water repletion (cardiac failure, oedema). "
01/01/1979 - "526 patients with essential hypertension or congestive cardiac failure were treated with ticrynafen (250--500 mg/day) or hydrochlorothiazide (50--100 mg/day) for 6 weeks to 6 months. "
10/01/1983 - "[Diflurex (tienilic acid) in the treatment of gout]."
01/01/1979 - "The safety and efficacy of tienilic acid have been evaluated in studies of patients with mild to moderate essential hypertension, salt and water retention states and hyperuricaemia associated with gout. "
08/01/1980 - "Controlled inpatient study of tienilic acid in treatment of gout and hypertension."
08/01/1980 - "Under inpatient controlled conditions 4 patients with gout and hypertension were treated with varying doses of tienilic acid, a new uricosuric diuretic. "
01/01/1980 - "Tienilic acid in the treatment of gout and hypertension."
|4.||Renal Insufficiency (Renal Failure)
01/01/1982 - "Thus, in these patients with renal insufficiency, ticrynafen still demonstrated a uricosuric effect as well as a useful anti-hypertensive action."
01/01/1982 - "Thus, although ticrynafen caused a significant reduction in blood pressure in this group of hypertensive patients with renal insufficiency, it was not consistently different from that which could be achieved with hydrochlorothiazide. "
01/01/1982 - "The efficacy of ticrynafen in the treatment of hypertension in patients with moderate renal impairment was compared with that of hydrochlorothiazide in a randomised, double-blind crossover trial in eleven subjects with renal insufficiency. "
05/01/1983 - "6 There were no problems with renal failure or urate deposition probably because patients were instructed to drink plenty of fluid when tienilic acid was started, because initial dose was low and because all previous diuretics were stopped for 3 days before tienilic acid was started. "
|5.||Hypoprothrombinemias (Prothrombin Deficiency)
09/01/1982 - "Thus, ticrynafen probably augments the hypoprothrombinemia of racemic warfarin by reducing metabolic clearance of S-warfarin. "
09/01/1982 - "To examine the ticrynafen-warfarin interaction, normal subjects received large single doses of 1.5 mg/kg racemic warfarin with and without daily oral doses of 250 mg ticrynafen beginning 3 days before warfarin and continuing for the duration of hypoprothrombinemia. "
08/15/1983 - "Ticrynafen administration enhanced the degree of hypoprothrombinemia and altered plasma and hepatic vitamin K epoxide concentrations in warfarin-treated rats. "
|2.||Uric Acid (Urate)
|5.||Ethacrynic Acid (Etacrynic Acid)
|9.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|10.||Ticrynafen (Tienilic Acid)